Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Decline Effect in Cardiovascular Medicine: Is the Effect of Cardiovascular Medicine and Stent on Cardiovascular Events Decline Over the Years?

  • Lee, Moo-Sik (Division of Cardiovascular Diseases, Mayo Clinic) ;
  • Flammer, Andreas J. (Division of Cardiovascular Diseases, Mayo Clinic) ;
  • Lerman, Amir (Division of Cardiovascular Diseases, Mayo Clinic)
  • Published : 2013.07.30
⟨ Previous Next ⟩

Abstract

The term decline effect is referred to a diminution of scientifically discovered effects over time. Reasons for the decline effect are multifaceted and include publication bias, selective reporting, outcomes reporting bias, regression to the mean, scientific paradigm shift, overshadowing and habituation, among others. Such effects can be found in cardiovascular medicines through medications (e.g., aspirin, antithrombotics, proton pump inhibitor, beta-blockers, statins, estrogen/progestin, angiotensin converting enzyme inhibitor etc.), as well as with interventional devices (e.g., angioplasty, percutaneous coronary intervention, stents). The scientific community should understand the various dimensions of the decline effects, and effective steps should be undertaken to prevent or recognize such decline effects in cardiovascular medicines.

Keywords

References

  1. Schooler J. Unpublished results hide the decline effect. Nature 2011;470:437. https://doi.org/10.1038/470437a
  2. Lehrer J. The Truth Wears Off-is there something wrong with the scientific method? New Yorker 2010. December 13.
  3. Moller AP, Jennions MD. Testing and adjusting for publication bias. Trends Ecol Evol 2001;16:580-6. https://doi.org/10.1016/S0169-5347(01)02235-2
  4. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008;3:e3081. https://doi.org/10.1371/journal.pone.0003081
  5. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007;176:1091-6. https://doi.org/10.1503/cmaj.060410
  6. Palmer AR. Quasi-replication and the contract of error: lessons from sex ratios, heritabilities and fluctuating asymmetry. Annu Rev Ecol Syst 2000;31:441-80. https://doi.org/10.1146/annurev.ecolsys.31.1.441
  7. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science 1999;284:1670-2. https://doi.org/10.1126/science.284.5420.1670
  8. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218-28. https://doi.org/10.1001/jama.294.2.218
  9. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62. https://doi.org/10.1056/NEJM199109123251102
  10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208. https://doi.org/10.1001/jama.1995.03520270033028
  11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. https://doi.org/10.1001/jama.288.3.321
  12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13. https://doi.org/10.1001/jama.280.7.605
  13. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6. https://doi.org/10.1056/NEJM199305203282004
  14. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9. https://doi.org/10.1056/NEJM199305203282003
  15. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6. https://doi.org/10.1016/S0140-6736(96)90866-1
  16. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60. https://doi.org/10.1056/NEJM200001203420302
  17. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9. https://doi.org/10.1056/NEJM199303113281001
  18. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2003:CD001560.
  19. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501. https://doi.org/10.1056/NEJM199408253310802
  20. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloonexpandable- stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95. https://doi.org/10.1056/NEJM199408253310801
  21. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-86. https://doi.org/10.7326/0003-4819-138-10-200305200-00005
  22. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11. https://doi.org/10.1016/0140-6736(93)92876-U
  23. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003;57:904-8. https://doi.org/10.1038/sj.ejcn.1601624
  24. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35. https://doi.org/10.1056/NEJM198907203210301
  25. US Preventive Services Task Force. Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins;1996.
  26. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405-10. https://doi.org/10.7326/0003-4819-150-6-200903170-00009
  27. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60. https://doi.org/10.7326/0003-4819-136-2-200201150-00015
  28. U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease [accessed on July 17, 2013]. Available from: http:// www.uspreventiveservicestaskforce.org/uspstf09/aspirincvd/aspcvdrs.htm.
  29. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796-801. https://doi.org/10.1016/j.amjcard.2011.02.325
  30. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42. https://doi.org/10.1056/NEJMoa0909475
  31. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard- dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43. https://doi.org/10.1016/S0140-6736(10)61088-4
  32. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011;8:547-59. https://doi.org/10.1038/nrcardio.2011.96
  33. Bonaca MP, Steg PG, Feldman LJ, et al. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol 2009;54:969-84. https://doi.org/10.1016/j.jacc.2009.03.083
  34. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-69. https://doi.org/10.2165/00019053-200624020-00005
  35. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9. https://doi.org/10.1161/01.CIR.102.6.624
  36. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52:1502-17. https://doi.org/10.1016/j.jacc.2008.08.002
  37. Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J 2009;157:412-22. https://doi.org/10.1016/j.ahj.2008.11.019
  38. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7. https://doi.org/10.1067/mhj.2002.126115
  39. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 2003;146:628-34. https://doi.org/10.1016/S0002-8703(03)00165-0
  40. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44. https://doi.org/10.1161/01.CIR.0000050144.67910.13
  41. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends Cardiovasc Med 2005;15:41-5. https://doi.org/10.1016/j.tcm.2005.01.002
  42. Douketis JD. Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why? Thromb Res 2011;127:513-7. https://doi.org/10.1016/j.thromres.2011.02.010
  43. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-2.
  44. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-71. https://doi.org/10.1056/NEJM199812033392303
  45. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404. https://doi.org/10.7326/0003-4819-150-6-200903170-00008
  46. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, lowdose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008;168:1684-90; discussion 1691. https://doi.org/10.1001/archinte.168.15.1684
  47. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Costutility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218-25. https://doi.org/10.1001/archinternmed.2010.525
  48. Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol 2011;8:7-8. https://doi.org/10.1038/nrcardio.2010.185
  49. Gurbel PA, Tantry US, Kereiakes DJ. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf 2010;2:233-40.
  50. US Department of Health & Human services; FDA. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC); 2009 [accessed on July 2, 2012]. Available from: http://www. fda.gov/Drugs/Drugsafety/PostmarketDrugsafetyinformationforPatientsandProviders/DrugsafetyinformationforHeathcareProfessionals/ucm190787.htm.
  51. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors; 2009 [accessed on July 17, 2013]. Available from: www.ema.europa.eu/humandocs/PDFs/ePAR/Plavix/32895609en.pdf.
  52. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619-33. https://doi.org/10.1161/CIR.0b013e318202f701
  53. Spoladore R, Fragasso G, Montanaro C, et al. [Present trends and controversies in the use of beta-blockers in cardiovascular diseases]. Recenti Prog Med 2010;101:429-41.
  54. Corteville B, Gillebert TC. Beta-blockers in uncomplicated arterial hypertension: what is the evidence? Tijdschrift voor Geneeskunde 2010;66;213-21.
  55. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53. https://doi.org/10.1016/S0140-6736(05)67573-3
  56. De Caterina AR, Leone AM. The role of Beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011;13:147-53. https://doi.org/10.1007/s11883-010-0157-9
  57. Frohlich ED. Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists. Ther Adv Cardiovasc Dis 2009;3:455-64. https://doi.org/10.1177/1753944709346519
  58. Weir MR. Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med 2009;121:90-8. https://doi.org/10.3810/pgm.2009.05.2007
  59. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010;8:733-41. https://doi.org/10.2174/157016110793563861
  60. Frishman WH, Saunders E. $\beta$-Adrenergic blockers. J Clin Hypertens (Greenwich) 2011;13:649-53. https://doi.org/10.1111/j.1751-7176.2011.00515.x
  61. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25. https://doi.org/10.1111/j.1472-8206.2004.00299.x
  62. Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ 2011;183:E1189-202. https://doi.org/10.1503/cmaj.101280
  63. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295:2046-56. https://doi.org/10.1001/jama.295.17.2046
  64. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83. https://doi.org/10.1161/01.CIR.103.2.276
  65. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35. https://doi.org/10.1161/01.CIR.97.12.1129
  66. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50. https://doi.org/10.1001/jama.279.20.1643
  67. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999;33:1294-304. https://doi.org/10.1016/S0735-1097(99)00018-2
  68. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol 2008;51:62-70. https://doi.org/10.1097/FJC.0b013e31815bb629
  69. Rutishauser J. Statins in clinical medicine. Swiss Med Wkly 2011;141: w13310.
  70. Sposito AC, Santos SN, de Faria EC, et al. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol 2011;31:1240-6. https://doi.org/10.1161/ATVBAHA.110.218685
  71. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? Am Coll Cardiol 2009;54:1425-33. https://doi.org/10.1016/j.jacc.2009.04.093
  72. Kopecky SL. New statin intolerance clinic. Mayo Clinic Cardiovascular Update 2010;8:6-7.
  73. Zhou Z, Rahme E, Pilote L. Association between time of statin initiation after hospital discharge from acute myocardial infarction and risk of recurrence and mortality in patients > or =65 years of age. Am J Cardiol 2006;97:155-9. https://doi.org/10.1016/j.amjcard.2005.07.135
  74. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-95. https://doi.org/10.1001/jama.287.23.3087
  75. Li YH, Wu HL, Yang YH, Tsai HS, Chao TH. Effect of early versus late inhospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J 2007;48:677-88. https://doi.org/10.1536/ihj.48.677
  76. Dabhadkar KC, Kulshreshtha A, Ali MK, Narayan KM. Prospects for a cardiovascular disease prevention polypill. Annu Rev Public Health 2011;32:23-38. https://doi.org/10.1146/annurev-publhealth-031210-101214
  77. Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary by pass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol 1981;48:765-77. https://doi.org/10.1016/0002-9149(81)90156-9
  78. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation 1982;66:14-22. https://doi.org/10.1161/01.CIR.66.1.14
  79. Hilliard AA, From AM, Lennon RJ, et al. Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv 2010;3:172-9. https://doi.org/10.1016/j.jcin.2009.11.013
  80. Park SJ, Park DW. Left main stenting. Circ J 2011;75:749-55. https://doi.org/10.1253/circj.CJ-11-0217
  81. Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes 2011;4:193-7. https://doi.org/10.1161/CIRCOUTCOMES.110.958744
  82. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000;284:1828-36. https://doi.org/10.1001/jama.284.14.1828
  83. Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheter Cardiovasc Interv 1999;48:262-8. https://doi.org/10.1002/(SICI)1522-726X(199911)48:3<262::AID-CCD5>3.0.CO;2-4
  84. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart 2001;85:667-71. https://doi.org/10.1136/heart.85.6.667
  85. Li JJ, Ren Y, Chen KJ, et al. Impact of C-reactive protein on in-stent restenosis: a meta-analysis. Tex Heart Inst J 2010;37:49-57.
  86. Sakhuja R, Mauri L. Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data. Annu Rev Med 2010;61:215-31. https://doi.org/10.1146/annurev.med.051508.221014
  87. Ejiri K, Ishihara M, Dai K, et al. Three-year follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. Circ J 2012;76:65-70. https://doi.org/10.1253/circj.CJ-11-0300
  88. Widimsky P. Primary angioplasty vs. thrombolysis: the end of the controversy? Eur Heart J 2010;31:634-6. https://doi.org/10.1093/eurheartj/ehp535
  89. Kadota K, Mitsudo K. Percutaneous coronary intervention with drugeluting stent for unprotected left main trunk disease: safety and efficacy compared with bare metal stent. -Which coronary stent should be used for the left main trunk disease? BMS or DES? (DES side)-. Circ J 2011;75:1250-4. https://doi.org/10.1253/circj.CJ-11-0307
  90. Kaneko H, Kijima M. Role of bare-metal stents for left main coronary artery disease in the era of drug-eluting stents. -Which coronary stent should be used for left main trunk disease? BMS or DES? (BMSside)-. Circ J 2011;75:1243-9. https://doi.org/10.1253/circj.CJ-11-0234
  91. Joviliano EE, Piccinato CE, Dellalibera-Joviliano R, Moriya T, Évora PR. Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. Ann Vasc Surg 2011;25:846-55. https://doi.org/10.1016/j.avsg.2011.02.026
  92. Räber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011;29:176-89. https://doi.org/10.1111/j.1755-5922.2010.00144.x
  93. Barbash IM, Waksman R. Current status, challenges and future directions of drug-eluting balloons. Future Cardiol 2011;7:765-74. https://doi.org/10.2217/fca.11.56
  94. Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials 1993;Doc No 50.
  95. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A 2001;98:831-6. https://doi.org/10.1073/pnas.98.3.831
  96. Trikalinos TA, Churchill R, Ferri M, et al. Effect sizes in cumulative meta- analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004;57:1124-30. https://doi.org/10.1016/j.jclinepi.2004.02.018
  97. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5. https://doi.org/10.1136/bmj.315.7109.640
  98. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-8. https://doi.org/10.1001/jama.1992.03480030052036
  99. Decullier E, Chapuis F. Impact of funding on biomedical research: a retrospective cohort study. BMC Public Health 2006;6:165. https://doi.org/10.1186/1471-2458-6-165
  100. von Elm E, Röllin A, Blümle A, Huwiler K, Witschi M, Egger M. Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly 2008;138:197-203.
  101. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72. https://doi.org/10.1016/0140-6736(91)90201-Y
  102. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998;279:281-6. https://doi.org/10.1001/jama.279.4.281
  103. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. Appl Stat 2000;49:359-70.
  104. Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat Methods Med Res 2005;14:515-24. https://doi.org/10.1191/0962280205sm415oa
  105. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol 2007;60:241-9. https://doi.org/10.1016/j.jclinepi.2006.06.016
  106. Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd. London: BMJ Publishing Group;2001.